263 related articles for article (PubMed ID: 34589991)
1. Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With
Wu SG; Liao WY; Su KY; Yu SL; Huang YL; Yu CJ; Chih-Hsin Yang J; Shih JY
JTO Clin Res Rep; 2021 Feb; 2(2):100140. PubMed ID: 34589991
[TBL] [Abstract][Full Text] [Related]
2. Large-scale clinico-genomic profile of non-small cell lung cancer with KRAS G12C: Results from LC-SCRUM-Asia study.
Tamiya Y; Matsumoto S; Zenke Y; Yoh K; Ikeda T; Shibata Y; Kato T; Nishino K; Nakamura A; Furuya N; Miyamoto S; Kuyama S; Nomura S; Ikeno T; Udagawa H; Sugiyama E; Nosaki K; Izumi H; Sakai T; Hashimoto N; Goto K
Lung Cancer; 2023 Feb; 176():103-111. PubMed ID: 36634571
[TBL] [Abstract][Full Text] [Related]
3. Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy.
Cefalì M; Epistolio S; Ramelli G; Mangan D; Molinari F; Martin V; Freguia S; Mazzucchelli L; Froesch P; Frattini M; Wannesson L
J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329953
[TBL] [Abstract][Full Text] [Related]
4. A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.
Kartolo A; Feilotter H; Hopman W; Fung AS; Robinson A
Cancer Treat Res Commun; 2021; 27():100330. PubMed ID: 33581492
[TBL] [Abstract][Full Text] [Related]
5. A Real-World Study in Advanced Non-Small Cell Lung Cancer with KRAS Mutations.
Lei L; Wang WX; Yu ZY; Liang XB; Pan WW; Chen HF; Wang LP; Fang Y; Wang M; Xu CW; Fang MY
Transl Oncol; 2020 Feb; 13(2):329-335. PubMed ID: 31881505
[TBL] [Abstract][Full Text] [Related]
6. [Gene mutation profiles and clinicopathological features of patients with non-small cell lung cancer harboring KRAS G12C mutation: a single-center retrospective study].
Guo LY; Xiang C; Zhao RY; Chen SN; Ma SJ; Han YC
Zhonghua Bing Li Xue Za Zhi; 2023 Feb; 52(2):117-123. PubMed ID: 36748130
[No Abstract] [Full Text] [Related]
7. KRAS G12C mutated advanced non-small cell lung cancer (NSCLC): Characteristics, treatment patterns and overall survival from a Danish nationwide observational register study.
Frost MG; Jensen KJ; Gotfredsen DR; Sørensen AMS; Ankarfeldt MZ; Louie KS; Sroczynski N; Jakobsen E; Andersen JL; Jimenez-Solem E; Petersen TS
Lung Cancer; 2023 Apr; 178():172-182. PubMed ID: 36868178
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and prognostic value of the
Liu SY; Sun H; Zhou JY; Jie GL; Xie Z; Shao Y; Zhang X; Ye JY; Chen CX; Zhang XC; Zhou Q; Yang JJ; Wu YL
Biomark Res; 2020; 8():22. PubMed ID: 32607238
[TBL] [Abstract][Full Text] [Related]
10. A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease.
Spira AI; Tu H; Aggarwal S; Hsu H; Carrigan G; Wang X; Ngarmchamnanrith G; Chia V; Gray JE
Lung Cancer; 2021 Sep; 159():1-9. PubMed ID: 34293517
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma.
Tao L; Miao R; Mekhail T; Sun J; Meng L; Fang C; Guan J; Jain A; Du Y; Allen A; Rzeszutko BL; Socinski MA; Chang CC
Clin Lung Cancer; 2021 Jul; 22(4):e506-e511. PubMed ID: 32807653
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Implication of
Noordhof AL; Swart EM; Damhuis RAM; Hendriks LEL; Kunst PWA; Aarts MJ; van Geffen WH
JTO Clin Res Rep; 2023 Sep; 4(9):100543. PubMed ID: 37674812
[TBL] [Abstract][Full Text] [Related]
13. KRAS mutated Non-Small Lung Carcinoma: A Real World Context from the Indian subcontinent.
Batra U; Nathany S; Sharma M; Bp A; Jose JT; Singh H; Mattoo S; Mehta A
Cancer Med; 2023 Feb; 12(3):2869-2874. PubMed ID: 36069080
[TBL] [Abstract][Full Text] [Related]
14. Molecular Signatures of
Hsu J; Annunziata JF; Burns E; Bernicker EH; Olsen RJ; Thomas JS
Clin Pathol; 2022; 15():2632010X221102054. PubMed ID: 35634237
[TBL] [Abstract][Full Text] [Related]
15. The Prognostic Effect of
Wahl SGF; Dai HY; Emdal EF; Berg T; Halvorsen TO; Ottestad AL; Lund-Iversen M; Brustugun OT; Førde D; Paulsen EE; Donnem T; Andersen S; Grønberg BH; Richardsen E
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503114
[TBL] [Abstract][Full Text] [Related]
16. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
Araujo LH; Souza BM; Leite LR; Parma SAF; Lopes NP; Malta FSV; Freire MCM
BMC Cancer; 2021 Feb; 21(1):193. PubMed ID: 33632153
[TBL] [Abstract][Full Text] [Related]
17. Survival of patients with KRAS G12C mutated stage IV non-small cell lung cancer with and without brain metastases treated with immune checkpoint inhibitors.
Swart EM; Noordhof AL; Damhuis RAM; Kunst PWA; De Ruysscher DKM; Hendriks LEL; van Geffen WH; Aarts MJ
Lung Cancer; 2023 Aug; 182():107290. PubMed ID: 37419045
[TBL] [Abstract][Full Text] [Related]
18. KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).
Sebastian M; Eberhardt WEE; Hoffknecht P; Metzenmacher M; Wehler T; Kokowski K; Alt J; Schütte W; Büttner R; Heukamp LC; Stenzinger A; Jänicke M; Fleitz A; Zacharias S; Dille S; Hipper A; Sandberg M; Weichert W; Groschek M; von der Heyde E; Rauh J; Dechow T; Thomas M; Griesinger F;
Lung Cancer; 2021 Apr; 154():51-61. PubMed ID: 33611226
[TBL] [Abstract][Full Text] [Related]
19. Outcomes and prognostic contributors in patients with
Burns EA; Ensor JE; Hsu J; Thomas JS; Olsen RJ; Bernicker EH
J Thorac Dis; 2021 Aug; 13(8):4785-4796. PubMed ID: 34527319
[TBL] [Abstract][Full Text] [Related]
20. KRAS mutation predict response and outcome in advanced non-small cell lung carcinoma without driver alterations receiving PD-1 blockade immunotherapy combined with platinum-based chemotherapy: a retrospective cohort study from China.
Li Q; Zhou Q; Zhao S; Wu P; Shi P; Zeng J; Xiong X; Chen H; Kittaneh M; Bravaccini S; Zanoni M; Zhou C; Zhang J
Transl Lung Cancer Res; 2022 Oct; 11(10):2136-2147. PubMed ID: 36386464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
